Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Predictors for brain metastases in metastatic breast cancer (BC) include aggressive tumor features. While overall survival remains poor, HER2-positive BC patients show improved outcomes, highlighting the need for personalized treatment strategies.
Area Of Science
- Oncology
- Cancer Research
Background
- Metastatic breast cancer (BC) treatment has advanced, yet long-term outcomes for patients with brain metastases are not well-defined.
- Brain metastases represent a significant challenge in advanced BC management.
Purpose Of The Study
- Identify predictors of brain metastases at initial diagnosis of stage IV BC.
- Describe overall survival (OS) trends over the past decade for these patients.
- Determine factors influencing OS after a brain metastases diagnosis.
Main Methods
- Utilized the Surveillance, Epidemiology, and End Results database (2010-2019) for de novo stage IV BC patients.
- Employed multivariate logistic regression to identify predictors of brain metastases.
- Applied Kaplan-Meier and Cox regression analyses to assess overall survival.
Main Results
- 1,939 patients with initial brain metastases were analyzed.
- Predictors included high-grade tumors, ductal histology, HR-negative/HER2-positive subtype, and extracranial metastases.
- HR-positive/HER2-positive disease showed the longest OS (median 18 months); factors like older age, lower income, and triple-negative subtype were linked to shorter OS.
Conclusions
- Median OS for BC with initial brain metastases remains poor despite treatment advances.
- A notable minority of patients survive 5+ years, particularly those with HER2-positive tumors.
- OS is influenced by tumor subtype, age, extracranial disease, and sociodemographic factors.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...